Article
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy - 1 Sept 2008
Marcelin Anne-Genevieve, Masquelier Bernard, Descamps Diane, Izopet Jacques, Charpentier Charlotte, Alloui Chakib, Bouvier-Alias Magali, Signori-Schmuck Anne, Montes Brigitte, Chaix Marie-Laure, Amiel Corinne, Santos Georges Dos, Ruffault Annick, Barin Francis, Peytavin Gilles, Lavignon Marc, Flandre Philippe, Calvez Vincent
Abstract excerpt
To identify mutations associated with the virological response (VR) to a tipranavir-ritonavir (TPV/r)-based regimen, 143 patients previously treated with protease inhibitor (PI) were studied. VR was defined by a decrease of at least 1 log(10) in, or undetectable, human immunodeficiency virus (HIV) RNA at month 3. The effect of each mutation in the protease, considering all variants at a residue as a single...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.